Clinical Trials Browser

Phase 2 × Myeloproliferative Disorders × olverembatinib × Clear all

NCT05521204 2022-08-30

Olverembatinib for FGFR1-rearranged Neoplasms

Phase 2 Recruiting

Myeloproliferative Disorders